Your Premier Source for AI-Powered Animal Health Business Insights
SOCIAL MEDIA LINKS
Your Premier Source for AI-Powered Animal Health Business Insights
SOCIAL MEDIA LINKS
Boehringer Ingelheim brought Turkiye’s poultry industry together in Istanbul on 30 October–1 November for the official launch of Prevexxion RN, its next-generation vaccine developed to strengthen Marek disease protection in breeder and layer operations. Designed as both a scientific and business-oriented gathering, the launch positioned Prevexxion RN as a strategic tool for integrations seeking stronger biological security and more stable production economics.
A Launch Framed Around Sector Needs and Economic Realities
The introduction of Prevexxion RN comes at a time when poultry businesses across Turkiye face increasing pressure to maintain uniformity, preserve breeder value and protect flock performance against evolving field strains. The launch emphasized that while modern integrations have advanced genetics and high-capacity systems, hidden Marek impacts
continue to impose significant economic drag—making stronger first-day protection more valuable than ever. With this context, the event set the stage for Prevexxion RN not merely as a new vaccine but as a risk-management investment for integrators.
Satellite Symposium as the Scientific Centerpiece of the Launch
The most anticipated component of the launch was the satellite symposium, which provided scientific depth and reinforced the economic relevance of stronger Marek control.
The session opened with Dr. Isabel Gimeno, an internationally renowned Marek expert, who explained the silent and often underestimated losses caused by the disease. She pointed out that subclinical Marek—immunosuppression, uneven flock performance, higher secondary infection risk—remains one of the most costly issues for integrations despite routine vaccination.
Gimeno emphasized:
“The real cost of Marek is not only what we see—it’s also what we fail to detect in flock performance.”
Her message tied directly to the financial pressures companies face when deviations in FCR, uniformity or breeder productivity accumulate over thousands or millions of birds.
Next, Dr. Stephane Lemiere presented the technical backbone of Prevexxion RN, explaining how its vaccine design aims to stabilize early immunity, enhance protection against virulent field strains and support more predictable performance outcomes. For businesses, this translates into fewer unexpected losses, more consistent production curves and stronger operational resilience.
Industry Expertise Frames the Bigger Picture
The overall launch agenda also featured short contributions from Prof. Dr. Mehmet Akan, Dr. Tolga Erkus and Murat Yakar, highlighting the interconnectedness of Marek control, chick quality and breeder management. Their presence reinforced the message that sustainable productivity depends on both biological protection and operational discipline, although their full analyses will be covered in separate articles.
A Strategic Launch for Turkiye’s Poultry Sector
The Prevexxion RN launch concluded with a networking dinner, finalizing an event that underscored Boehringer Ingelheim’s commitment to supporting the long-term economic strength of Turkiye’s poultry industry.
By combining scientific innovation, economic insight and expert engagement, the launch positioned Prevexxion RN as a forward-looking solution for integrations seeking better stability, performance predictability and protection against hidden Marek-related losses.
For further info: Boehringer Ingelheim Animal Health
All rights reserved to The Animal Economics © Copyright 2026 | Web design & implementation: PAQ Consultancy
This website uses cookies. For details, please see our privacy policy. By clicking on the relevant button or any other element of the page, you consent to the use of cookies.
